共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
Virological efficacy with first‐line antiretroviral treatment in India: predictors of viral failure and evidence of viral resuppression 下载免费PDF全文
Anita Shet Ujjwal Neogi N. Kumarasamy Ayesha DeCosta Suresh Shastri Bharat Bhushan Rewari 《Tropical medicine & international health : TM & IH》2015,20(11):1462-1472
3.
4.
5.
6.
7.
Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV‐positive persons: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study 下载免费PDF全文
CI Hatleberg L Ryom A d'Arminio Monforte E Fontas P Reiss O Kirk W El‐Sadr A Phillips S de Wit F Dabis R Weber M Law JD Lundgren C Sabin the Data Collection on Adverse Events of Anti‐HIV Drugs Study Group 《HIV medicine》2018,19(9):605-618
8.
9.
10.
Mortality and clinical outcomes in children treated with antiretroviral therapy in four African vertical programmes during the first decade of paediatric HIV care, 2001–2010 下载免费PDF全文
Jihane Ben‐Farhat Birgit Schramm Nathalie Nicolay Stephen Wanjala Elisabeth Szumilin Suna Balkan Mar Pujades‐Rodríguez 《Tropical medicine & international health : TM & IH》2017,22(3):340-350
11.
12.
More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV‐infected patients with or without HBV and HCV co‐infections 下载免费PDF全文
Y. Ding S. Duan R. Ye Y. Yang S. Yao J. Wang D. Cao X. Liu L. Lu M. Jia Z. Wu N. He 《Journal of viral hepatitis》2017,24(5):412-420
We examined the effect of combination antiretroviral therapy (cART) on liver fibrosis among HIV‐infected patients with or without hepatitis B (HBV) or C virus (HCV) co‐infection. This was a retrospective cohort study of HIV‐infected patients receiving cART during 2004‐2016. Liver fibrosis was assessed using Fibrosis‐4 (FIB‐4) score with three classifications: Class 1, <1.45; Class 2, 1.45‐3.25; Class 3, >3.25. Of 3900 participants, 68.6% were HIV mono‐infected, 5.3% were HIV/HBV co‐infected, 23.8% were HIV/HCV co‐infected and 2.3% were HIV/HBV/HCV co‐infected. Participants received follow‐up treatment (median was 3.3 years). Improvement to a lower class was observed in Class 2 (52.6%) and Class 3 (74.2%), respectively. Progression to a higher class was observed in 12.8% and 5.0% in Class 1 and Class 2, respectively, and with a median time of 5.7 months. For improvement to lower classes, older age, male, Dai ethnicity, injection drug use, HCV co‐infection and tenofovir for treatment were negative predictors, but in Class 3 of FIB‐4 and time‐updated increases in CD4 count from baseline were positive predictors. For progression to higher classes, older age, male, Jingpo ethnicity and HCV co‐infection were positive predictors, while baseline CD4 count and in Class 2 of FIB‐4 were negative predictors. Improvement to lower class linked with decreased mortality risk among patients in Class 3. Early cART initiation for HIV‐infected patients with and without hepatitis co‐infections may mitigate or slow down some of liver fibrosis, but special attention should be given to those who are older, male, co‐infected with HCV. 相似文献
13.
14.
C. G. Tsiara G. K. Nikolopoulos N. L. Dimou P. G. Bagos G. Saroglou E. Velonakis A. Hatzakis 《Journal of viral hepatitis》2013,20(10):715-724
Co‐infection of human immunodeficiency virus (HIV) with hepatitis C virus (HCV) is rather common. In the era of highly active antiretroviral therapy (HAART), viral hepatitis could result in adverse outcomes in HIV+ patients. The current meta‐analysis aims to evaluate the impact of HCV on immunological and virological responses after HAART initiation in HIV/HCV co‐infected individuals by synthesizing the existing scientific evidence. A comprehensive search of electronic databases was performed. Eligible studies were analysed using univariate and multivariate meta‐analytic methods. Totally, 21 studies involving 22533 individuals were eligible. The estimated summary difference in CD4 cell counts increase between HIV and HIV/HCV co‐infected subjects after 3–12 months on HAART was 34.86 cells/mm3 [95% confidence interval (CI): 16.82–52.89]. The difference was more prominent in patients with baseline CD4 counts below 350 cells/mm3 (38.97, 95% CI: 20.00–57.93) and attenuated 2 years later (13.43, 95% CI: 0.83–26.04). The analysis of ratio measures yielded similar findings. The virological control remained unaffected by the presence of HCV (adjusted Hazard Ratio for co‐infected patients vs those with HIV alone: 0.99, 95% CI: 0.91–1.07). The bivariate meta‐analytic method confirmed the results of the univariate approaches. This meta‐analysis supports the adverse effect of HCV on immune recovery of HIV+ patients initiating HAART, especially of those with initially impaired immunologic status. Although this effect diminishes over time, early administration of HAART in the setting of co‐infection seems to be justified. 相似文献
15.
16.
17.
18.
19.
Treatment outcomes of over 1000 patients on second‐line,protease inhibitor‐based antiretroviral therapy from four public‐sector HIV treatment facilities across Johannesburg,South Africa 下载免费PDF全文
Kate Shearer Denise Evans Faith Moyo Julia K. Rohr Rebecca Berhanu Liudmyla Van Den Berg Lawrence Long Ian Sanne Matthew P. Fox 《Tropical medicine & international health : TM & IH》2017,22(2):221-231
20.
P. Pradat M.‐A. Le Pogam J.‐B. Okon P. Trolliet P. Miailhes C. Brochier M. Maynard F. Bailly F. Zoulim L. Cotte 《Journal of viral hepatitis》2013,20(9):650-657
We aimed to compare the evolution of estimated glomerular filtration rate (eGFR) in HIV‐, HIV–HBV‐ and HBV‐infected patients treated with tenofovir disoproxil fumarate (TDF). Three groups of patients receiving TDF > 12 months were recruited: 194 HIV‐infected patients, 85 HIV–HBV‐coinfected patients and 50 HBV‐infected patients. eGFR was estimated using the Modification of the Diet in Renal Disease (MDRD) equation. Multivariate regression models were constructed to estimate factors associated with eGFR decrease from baseline. A total of 329 patients were studied. Median follow‐up was 2.7 years. Median eGFR decrease was ?4.9 (?16.6 to +7.2) mL/min/1.73 m2. After multivariate stepwise regression analysis, age (P = 0.0002), non‐African origin (P < 0.0001), baseline eGFR (P < 0.0001) and TDF duration (P = 0.02) were associated with eGFR decrease in the whole population, while hypertension, diabetes and type of infection were not. Age (P < 0.0001), non‐African origin (P = 0.0004), baseline eGFR (P < 0.0001) and TDF duration (P = 0.007) remained associated with eGFR decline in HIV and HIV–HBV‐infected patients, while other variables including HIV risk factor, CDC stage, CD4 and HIV‐RNA levels were not. Age (P = 0.03), non‐African origin (P = 0.004), baseline eGFR (P < 0.0001) and baseline HBV–DNA > 2000 IU/mL (P = 0.04) were associated with eGFR decline in HBV and HIV–HBV‐infected patients, while other variables including HBV risk factor and fibrosis stage were not. Estimated glomerular filtration rate decline under TDF therapy appears mainly associated with older age, non‐African origin, higher baseline eGFR and longer TDF administration but not with the type of viral infection. Regular follow‐up of renal function, especially tubular function is recommended during TDF therapy. 相似文献